Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Respiratory Journal Année : 2023

Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study

Gaëlle Dauriat
  • Fonction : Auteur
Laurence Beaumont
  • Fonction : Auteur
Liem Binh Luong Nguyen
Benjamin Renaud Picard
Morgane Penhouet
  • Fonction : Auteur
Benjamin Coiffard
  • Fonction : Auteur
Mathilde Salpin
  • Fonction : Auteur
Xavier Demant
  • Fonction : Auteur
Christel Saint Raymond
  • Fonction : Auteur
Nicolas Carlier
Jonathan Messika
Martine Reynaud Gaubert
  • Fonction : Auteur
Isabelle Danner
  • Fonction : Auteur
Floriane Gallais
Jérôme Le Pavec
  • Fonction : Auteur

Résumé

Question addressed by the study Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients? Methods We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264 BAU·mL −1 after the third dose (median (interquartile range (IQR)) 3.0 (1.7–4.1) months), was the primary outcome and adverse events were the secondary outcomes. Median (IQR) age at the first vaccine dose was 54 (40–63) years and median (IQR) time from transplantation to the first dose was 64 (30–110) months. Results Median (IQR) follow-up after the first dose was 8.3 (6.7–9.3) months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47/898 (5%)) and four (4/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1–7.3) months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease. Conclusions Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection via cellular immunity and/or good adherence to shielding measures.

Dates et versions

hal-04482163 , version 1 (28-02-2024)

Identifiants

Citer

Gaëlle Dauriat, Laurence Beaumont, Liem Binh Luong Nguyen, Benjamin Renaud Picard, Morgane Penhouet, et al.. Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study. European Respiratory Journal, 2023, 61 (1), pp.2200502. ⟨10.1183/13993003.00502-2022⟩. ⟨hal-04482163⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More